Ludwig Maximilian University of Munich

InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial

Retrieved on: 
Friday, November 3, 2023
FDA, Stem Cells, Pharmaceutical, Surgery, Physical Therapy, Managed Care, General Health, Hospitals, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Medical Supplies, Patient, Insurance, VAS, RT, Syndrome, Ludwig Maximilian University of Munich, Literature, Policy, Treatment, Visual analogue scale, Khaneqah Bala va Pain, Injection, OA, Pain, CSI, Osteoarthritis, KOOS, Evidence-based medicine, Cell, Clinical trial, Guideline, Knee, Emory University, MILES, Total, Knee pain, Gottschalk, Pharmaceutical industry, Medical imaging, InGeneron

InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).

Key Points: 
  • InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).
  • Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.
  • At InGeneron, we are dedicated to evidence-based medicine and deeply value our partnerships with respected institutions like Emory University.
  • Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.

Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, PSP, ORION, Progressive supranuclear palsy, Movement disorder, Pan Pacific Hotels and Resorts, Medication, MDS, Neurology, AMX0035, Disease, Aggregation, Ludwig Maximilian University of Munich, Unfolded protein response, HIV disease progression rates, LMU, Quality of life, Department of Neurology, Xuanwu hospital, Caregiver burden, Safety, Hospital, Pharmaceutical industry, Medical imaging, Amylyx Pharmaceuticals, MD

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced an upcoming presentation at Neuro2023 on the design of ORION, a planned global, Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [PB&TURSO]) in progressive supranuclear palsy (PSP).

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced an upcoming presentation at Neuro2023 on the design of ORION, a planned global, Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [PB&TURSO]) in progressive supranuclear palsy (PSP).
  • Neuro2023: The PSP and CBD International Research Symposium will take place on October 19-20, 2023, at the Pan Pacific Hotel in London, UK.
  • The ORION Phase 3 trial was designed and planned in collaboration with key global academic leaders, people living with PSP, and industry advocacy groups.
  • Additional details regarding trial enrollment and eligibility criteria will be shared upon initiation of the trial, which is anticipated to start by the end of 2023.

Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Friday, October 13, 2023
European, Quality of life, Biomarker, CHMP, Lead, DMD, European Commission, Safety, European Medicines Agency, Spine, Disease, Vamorolone, EMA, Dual-energy X-ray absorptiometry, FDA, Steroid, LR, Ludwig Maximilian University of Munich, Prednisone, NDA, EC, Growth, Neurology, DXA, Catalyst Pharmaceuticals, Associate, Patient, MA, Civil service commission, PDUFA, Pharmaceutical industry, Medical device, Medical imaging, Becker, MD, Duchenne, EU

Santhera plans for a first commercial launch in Germany in Q1-2024, subject to approval by the EC.

Key Points: 
  • Santhera plans for a first commercial launch in Germany in Q1-2024, subject to approval by the EC.
  • “We are thrilled about the CHMP’s positive opinion, which recognizes the urgent medical need for an effective and well tolerated treatment for this devastating disease.
  • “We are very excited about the positive opinion from the European Medicines Agency,” declared Ezio Magnano, President of Parent Project Italy.
  • A marketing authorization decision from the EC is expected within approximately two months of the positive CHMP opinion.

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Retrieved on: 
Friday, October 6, 2023
Clinical Science (journal), Ludwig Maximilian University of Munich, Cancer, Dana–Farber Cancer Institute, Department of Medicine – University of Pamplona, Faculty, Research, Clinical, Therapy, Case Western Reserve University, Hospital, Nature, Melanoma, Journal, Nivolumab, Carcinoma, Brigham and Women's Hospital, Harvard Medical School, Clinical trial, Associate, American Journal of Clinical Oncology, Principal investigator, Neoplasm, Patient, Vaccine, Pharmaceutical industry, New York University, Medicine

LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.
  • Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute.
  • He joins current scientific advisory board members Dan H. Barouch, M.D., Ph.D., Luke D. Handke, Ph.D., Sachet A. Shukla, Ph.D. and John W. Shiver, Ph.D.
    “We are honored that Dr. Ott has agreed to our scientific advisory board and believe that he will offer invaluable guidance as we further develop our technologies and advance our pipeline,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON.
  • Dr. Ott has been Principal Investigator of a first-in-human clinical trial testing a personalized vaccine (NeoVax) in patients with melanoma.

EQS-News: Endor AG: Matthias Kosch succeeds Andras Semsey as new CFO

Retrieved on: 
Friday, September 29, 2023
CFO, Financial Oversight and Management Board for Puerto Rico, Joel Kosche, Supervisory board, Munich University of Applied Sciences, Acquisition, Investment, Ludwig Maximilian University of Munich, Endor, Applied science, Landshut, Property management, Management

Landshut, September 29, 2023 – Endor AG, a global supplier of equipment for racing simulations, announces a change in the Management Board.

Key Points: 
  • Landshut, September 29, 2023 – Endor AG, a global supplier of equipment for racing simulations, announces a change in the Management Board.
  • As of November 1, 2023, the Supervisory Board appoints Matthias Kosch (born 1978) to the Management Board of Endor AG.
  • Andras Semsey, who has been a member of the Management Board since 2004, will not renew his contract, which expires on December 31, 2023.
  • As CFO, Matthias Kosch will have sole responsibility for the finance department at Endor AG as of January 1, 2024, as well as joint responsibility for the capital market with CEO Thomas Jackermeier.

Democratising access to quantum computing: IQM Quantum Computers launches “IQM Spark” for universities and labs

Retrieved on: 
Wednesday, August 30, 2023
Semiconductor, Security, Nanotechnology, Audio, Video, Other Science, Research, Other Technology, Artificial Intelligence, Software, Networks, Internet, Hardware, Data Management, Science, Technology, Mobile, Wireless, University, Education, Web3, CSC – IT Center for Science, Learning, VTT Technical Research Centre of Finland, VTT, Gottfried Wilhelm Leibniz, TUM, Electronics, Centre for Quantum Technologies, Institute of technology, CSC, Science, technology, engineering, and mathematics, Technical University of Munich, Multimedia, Doctor of Philosophy, Computer, IQM, LMU, Student, Algorithm, Quantum, Ludwig Maximilian University of Munich, STEM, Ecosystem, LUMI, Leibniz Supercomputing Centre, Nursing, Management, Microscope, Mathematics, Engineering

IQM Quantum Computers (IQM), the European leader in building quantum computers, today launched “IQM Spark,” comprising a superconducting quantum computer and tailored learning experiences for universities and research labs worldwide.

Key Points: 
  • IQM Quantum Computers (IQM), the European leader in building quantum computers, today launched “IQM Spark,” comprising a superconducting quantum computer and tailored learning experiences for universities and research labs worldwide.
  • To help universities kick-start their quantum program, in addition, universities will have free maintenance for one year, and IQM will also provide training for running the system and learning materials accessible through IQM Academy, a user-friendly online platform.
  • With IQM Spark, students of all levels (bachelor, master, and PhD) will have the opportunity to learn hands-on about quantum computing.
  • With its technical track record and world-class expertise, IQM is also committed to collaborating with universities to drive advancements in quantum science.

China University of Geosciences (Beijing) Research Offers New Insights into the Expanse of Greater India to Support India-Asia Collision in the Western Himalayas Dating Back to Circa 55 Million Years

Retrieved on: 
Tuesday, August 29, 2023
Ludwig Maximilian University of Munich, Greater, Indian Plate, Chinese Academy of Sciences, Planetary science, CUGB, National academy, China University of Geosciences, Rare-earth element, Greater India, Cretaceous, Himalayas, Himalayan

Greater India refers to a portion of the Indian plate that subducted under Asia, forming the Tibetan Plateau.

Key Points: 
  • Greater India refers to a portion of the Indian plate that subducted under Asia, forming the Tibetan Plateau.
  • To accurately estimate the kinematics and timing of the India–Asia collision, the extent of Greater India must be defined.
  • Professor Jun Meng from CUGB, the study's first author, explains, "There are two primary models for the India–Asia collision.
  • These findings augment our understanding of the India–Asia collision and the emergence of various geological structures in these regions.

Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Disease, Regulation Fair Disclosure, Ludwig Maximilian University of Munich, Disclosure, European Directive on Traditional Herbal Medicinal Products, Pan-Canadian Pharmaceutical Alliance, Brain, Research, Department of Neurology, Xuanwu hospital, Wolfram syndrome, Medication, EMA, Committee, Walking, Investment, Committee for Medicinal Products for Human Use, PEGASUS, Webcast, Neurology, AMX0035, Neurological disorder, ORION, MAA, Marketing Authorisation Application, European Medicines Agency, Palsy, ALS, Regulation, PSP, CHMP, Cryptocurrency, Pharmaceutical industry, Amylyx Pharmaceuticals, Wolfram

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the second quarter ended June 30, 2023.
  • Net product revenue for the three months ended June 30, 2023 was $98.2 million, compared to net product revenue of $71.4 million for the three months ended March 31, 2023.
  • Financial Results for the Second Quarter Ended June 30, 2023
    For the three months ended June 30, 2023, net product revenue was $98.2 million, and cost of sales were $5.6 million.
  • Cash, cash equivalents, and short-term investments were $357.3 million at June 30, 2023, compared to $345.7 million at March 31, 2023.

Velo3D Announces the Appointment of Dr. Adrian Keppler to Its Board of Directors

Retrieved on: 
Monday, July 31, 2023
Technology, Manufacturing, Semiconductor, Other Technology, Other Manufacturing, Software, Nanotechnology, Engineering, Hardware, Machine Tools, Metalworking & Metallurgy, Electronic Design Automation, EOS, University of Zurich, University, Original equipment manufacturer, Printing, 3D, Senior advisor, Geotechnical engineering, CMO, Doctor of Philosophy, Consultant, Ludwig Maximilian University of Munich, Business administration, Digital manufacturing, VLD, Siemens, Management, Knowledge, Growth, Digital, NYSE

Velo3D , Inc. ( NYSE: VLD ), a leading metal additive manufacturing technology company for mission-critical parts, has appointed Dr. Adrian Keppler to its Board of Directors.

Key Points: 
  • Velo3D , Inc. ( NYSE: VLD ), a leading metal additive manufacturing technology company for mission-critical parts, has appointed Dr. Adrian Keppler to its Board of Directors.
  • “Dr.
  • In addition, he is Senior Advisor for Digital Manufacturing at H&Z, a leading Management Consultancy in Europe.
  • Dr. Keppler holds a PhD in Geotechnical Engineering from Ludwig Maximilians University of Munich and a degree in Business Administration from the University of Zurich.

CordenPharma Establishes World-Class Technology & Science Advisory Board of Experts Across Six Technology Platforms

Retrieved on: 
Wednesday, July 26, 2023
Biochemistry, Business development, Drug development, University, Drug delivery, Organic chemistry, Approved Drug Products with Therapeutic Equivalence Evaluations, Institute of technology, Biotechnology, Lipid, MBA, OSD, Technical University of Berlin, RNA, University of Bonn, University of Graz, CDMO, Professor, Machine learning, Pharmaceutics, Knowledge, Growth, AI, API, LNP, Solid lipid nanoparticle, Oligonucleotide, Bipolar Integrated Technology, Pharmacology, Peptide, Fine chemical, Vaccine, Management, Biopharmaceutical, Chemistry, Ludwig Maximilian University of Munich

CDMO CordenPharma establishes world-class Technology & Science Advisory Board of experts across 6 technology platforms.

Key Points: 
  • CDMO CordenPharma establishes world-class Technology & Science Advisory Board of experts across 6 technology platforms.
  • The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.
  • Their collective expertise will provide valuable insights into emerging trends, cutting-edge technologies, and regulatory advancements across all six CordenPharma technology platforms .
  • Dr. Michael Quirmbach, CEO & President at CordenPharma, said: "CordenPharma is honored to have the opportunity to work with these distinguished scientific experts.